HBM Healthcare Investments Reports Strong Q1 Results

HBM Healthcare Investments announced a profit of CHF 238 million for the first quarter of the 2026/2027 financial year. As of 30 June 2026, the company's net assets surpassed CHF 2 billion. The net asset value per share increased by 13%, with a share price rise of 8.9%. The remaining 23% discount to NAV indicates further upside potential.

Public investments led to a contribution of CHF 183 million in the quarterly results, while private investments provided CHF 105 million. Key drivers included Eli Lilly's acquisition of Curevo Vaccine and IPOs of Parabilis Medicines and Odyssey Therapeutics. Notably, Dren Bio's financing round alone increased valuations by CHF 71 million.

HBM made new private investments in Lycia Therapeutics and CellCentric, advancing the private portfolio's growth. Looking forward, the healthcare sector's improving market conditions and successful IPOs suggest continued positive momentum.